Alethia is developing innovative therapeutic approaches in areas of unmet medical needs, capitalizing on its capacity to identify and validate disease-specific targets for the development of highly focused monoclonal antibody-based therapeutics. The company is currently focusing on cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and on cancer-induced bone loss.
Location: Canada, Quebec, Montreal
Total raised: $9.22M
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 08.09.2010 | Series A | $9.22M | - |
Mentions in press and media 3
| Date | Title | Description |
| 30.10.2023 | Alethia Raises $50 Million With a Beverage Focus | - |
| 02.11.2012 | Alethia Biotherapeutics Closes Financing | Alethia Biotherapeutics Inc., a Montréal, Québec, Canada-based biotechnology company focusing on the development of therapeutic monoclonal antibodies, has closed a new financing. Update: The investment amounts to $4.7m. The amount was not d... |
| 08.09.2010 | Alethia Biotherapeutics Closes C$9.6M Series A Round of Financing | Alethia Biotherapeutics Inc., a Montreal, Canada-based biopharmaceutical company focused on the development of monoclonal antibodies, has closed a C$9.6m Series A round of financing. The round was co-led by AgeChem Venture Fund, BDC Venture... |